VEXAS综合征的胸肺表现
常见表现为磨玻璃影(87%)、胸腔积液(53%),多数患者对泼尼松有改善但常需>20 mg/d。胸肺受累者与其余队列在主要临床生物学特征及中位生存上无差异,提示可能被低估。
要点
- VEXAS综合征患者胸肺受累常见,法国队列可评估者中39%经判定与本病相关。
- 胸部CT常见磨玻璃影(87%)、胸腔积液(53%),多数对泼尼松有改善但常需>20 mg/d。
- 胸肺受累者与其余队列主要特征及中位生存无差异,提示可能被低估。
核心结论
- VEXAS综合征中胸肺表现常见但很少为首发或突出表现,初始对泼尼松反应良好且似不导致肺纤维化。
主要发现
- 45例(39%)胸部CT异常经判定与VEXAS相关,其中男性95%,症状起病中位年龄67.0岁。
- 45例中44%有呼吸困难、40%有咳嗽;CT均见肺 opacity,包括磨玻璃影87%、实变49%、网格影38%、间隔线51%,53%有胸腔积液。
- 多数患者对泼尼松有改善但常需>20 mg/d;胸肺受累者与其余队列主要临床生物学特征及中位生存无差异。
关键数值与推荐
- 胸部CT肺 opacity 包括磨玻璃影87%、实变49%、网格影38%、间隔线51%,胸腔积液53%。
- 泼尼松改善常需>20 mg/d。
临床怎么用
- 对VEXAS综合征患者应关注胸肺受累可能,胸部CT可协助识别磨玻璃影、实变及胸腔积液等表现。
- 胸肺受累初始治疗可考虑泼尼松,但常需>20 mg/d,需权衡剂量与不良反应。
局限性
- 仅51例有胸部CT可评估,可能存在选择偏倚。
- 胸肺受累判定依赖多学科 adjudication,缺乏统一客观标准。
- 胸肺受累在其余队列中可能被低估,影响组间比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a newly identified autoinflammatory disorder related to somatic UBA1 mutations. Up to 72% of patients may show lung involvement. RESEARCH QUESTION: What are the pleuropulmonary manifestations in VEXAS syndrome? STUDY DESIGN AND METHODS: One hundred fourteen patients were included in the French cohort of VEXAS syndrome between November 2020 and May 2021. Each patient included in the study who had an available chest CT scan was discussed in an adjudication multidisciplinary team and classified as showing potentially pleuropulmonary-specific involvement of VEXAS syndrome or others. RESULTS: Fifty-one patients had a CT scan available for review and 45 patients (39%) showed pleuropulmonary abnormalities on chest CT scan that were considered related to VEXAS syndrome after adjudication. Most patients were men (95%) with a median age 67.0 years at the onset of symptoms. Among these 45 patients, 44% reported dyspnea and 40% reported cough. All 45 patients showed lung opacities on chest CT scan (including ground-glass opacities [87%], consolidations [49%], reticulation [38%], and septal lines [51%]) and 53% of patients showed pleural effusion. Most patients showed improvement with prednisone, but usually required > 20 mg/d. The main clinical and biological features as well the median survival did not differ between the 45 patients with pleuropulmonary involvement and the rest of the cohort, suggesting that the prevalence of pleuropulmonary involvement might have been underdiagnosed in the rest of the cohort. INTERPRETATION: Pulmonary manifestations are frequent in VEXAS syndrome, but rarely are at the forefront. The initial outcome is favorable with prednisone and does not seem to lead to pulmonary fibrosis.
引用
- Borie R, Debray MP, Guedon AF, et al. Pleuropulmonary Manifestations of Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome. Chest. 2022. PMID: 36272567. doi:10.1016/j.chest.2022.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。